However, the constitutive CDKN2A knockout mouse model used in this study and the fact, that alterations in the cell cycle pathway are common genetic events in human melanoma, make it unlikely that NRAS status alone is a marker for effective therapy with MEK+CDK4,6 inhibition. Here, NRAS is linked to melanoma.